Business Context and Reporting Period
This Form 8-K reports on the results of the 2022 Annual Meeting of Stockholders held by MacroGenics, Inc. on May 19, 2022. The meeting addressed four proposals regarding director elections, auditor ratification, and executive compensation.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
A total of 49,568,059 shares were present or represented by proxy, representing approximately 81% of the 61,324,758 shares outstanding as of the record date. All four proposals were approved:
- Proposal 1 (Director Election): Both Class III nominees, Karen Ferrante, M.D., and Edward Hurwitz, were elected.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2022.
- Proposal 3 (Say-on-Pay): Stockholders approved the compensation of named executive officers on an advisory basis.
- Proposal 4 (Say-on-Pay Frequency): Stockholders approved holding future advisory votes on executive compensation every year.
Guidance, Outlook, and Management Commentary
Based on the voting results for Proposal 4, the Board determined to hold future non-binding, advisory votes on executive compensation annually. The next such vote is scheduled for the 2023 Annual Meeting of Stockholders. The next vote regarding the frequency of these advisory votes is required no later than the 2028 Annual Meeting.
Important Facts for Investors to Verify
- Confirmation of the new Class III directors' terms and backgrounds.
- Review of the definitive proxy statement filed on April 8, 2022, for detailed executive compensation data.
- Verification of the 2023 Annual Meeting date for the next Say-on-Pay vote.